Clinical Trial Update: Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 trial investigating elotuzumab with anti-LAG-3 and anti-TIGIT antibodies for multiple myeloma has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Anti-LAG-3 antibody
• Anti-TIGIT antibody
• Elotuzumab (elotuzumab)

Snippet

Sponsor: Multiple Myeloma Research Consortium | Conditions: Multiple Myeloma, Relapsed Refractory Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED